We are live on ! Find out more
INZY

Inozyme Pharma
INZY

Delisted

INZY was delisted on the 30th of June, 2025.

Back to rankings

77 hedge funds and large institutions have $205M invested in Inozyme Pharma in 2023 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 31 increasing their positions, 19 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

108% more call options, than puts

Call options by funds: $866K | Put options by funds: $416K

63% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 19

30% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 10

8% more capital invested

Capital invested by funds: $190M → $205M (+$14.4M)

4% more funds holding

Funds holding: 74 → 77 (+3)

1.37% more ownership

Funds ownership: 77.56% → 78.93% (+1.4%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
77
Holders Change
+3
Holders Change %
+4.05%
% of All Funds
1.22%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
13
Increased
31
Reduced
19
Closed
10
Calls
$866K
Puts
$416K
Net Calls
+$450K
Net Calls Change
+$587K

Top Buyers

Rank Fund Capital Flow
1
SC
Samlyn Capital
New York
+$16.5M
2
EAM
Eventide Asset Management
Massachusetts
+$15.9M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$8.73M
4
SB
Samsara BioCapital
California
+$7.95M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$6.55M

Top Sellers

Rank Fund Capital Flow
1
DTC
Deep Track Capital
Connecticut
-$9.16M
2
Millennium Management
Millennium Management
New York
-$4.47M
3
WP
Woodline Partners
California
-$1.61M
4
Walleye Capital
Walleye Capital
New York
-$1.05M
5
EI
EAM Investors
California
-$982K
Name Holding Trade Value Shares
Change 		Change in
Stake
OMC
26
Overbrook Management Corp
New York
$921K – – –
PHP
27
Parkman Healthcare Partners
Connecticut
$739K +$36.1K +7,106 +4%
UOC
28
UBS O'Connor
Illinois
$652K – – –
Bank of New York Mellon
29
Bank of New York Mellon
New York
$593K -$2.86K -563 -0.4%
N
30
Nuveen
North Carolina
$579K – – –
Marshall Wace
31
Marshall Wace
United Kingdom
$570K +$40.1K +7,876 +6%
Citadel Advisors
32
Citadel Advisors
Florida
$563K -$59K -11,590 -8%
Two Sigma Advisers
33
Two Sigma Advisers
New York
$404K -$584K -114,900 -54%
Charles Schwab
34
Charles Schwab
California
$395K +$29.2K +5,738 +7%
Bank of America
35
Bank of America
North Carolina
$389K +$189K +37,123 +67%
GCP
36
GSA Capital Partners
United Kingdom
$389K +$335K +65,842 +246%
BCM
37
Bridgeway Capital Management
Texas
$385K -$127K -24,917 -21%
Two Sigma Investments
38
Two Sigma Investments
New York
$286K -$89K -17,487 -20%
Dimensional Fund Advisors
39
Dimensional Fund Advisors
Texas
$250K -$121K -23,755 -29%
Mirae Asset Global Investments
40
Mirae Asset Global Investments
South Korea
$233K – – –
Goldman Sachs
41
Goldman Sachs
New York
$226K +$99.2K +19,499 +57%
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
$193K +$12.8K +2,518 +6%
Squarepoint
43
Squarepoint
New York
$179K +$217K +42,607 New
Walleye Capital
44
Walleye Capital
New York
$147K -$1.05M -206,013 -85%
BC
45
BIT Capital
Germany
$122K – – –
DA
46
Denali Advisors
California
$112K – – –
Morgan Stanley
47
Morgan Stanley
New York
$111K -$36.7K -7,213 -21%
JP Morgan Chase
48
JP Morgan Chase
New York
$92.4K -$21.9K -4,305 -16%
AQR Capital Management
49
AQR Capital Management
Connecticut
$82.9K +$100K +19,744 New
UBS Group
50
UBS Group
Switzerland
$79.5K -$13.5K -2,660 -12%
1
2
3 4

INZY Hedge Fund Activity: Q3 2023 in Review

77 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q3 2023, worth a combined $205M — up 7.6% from $190M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new INZY positions and 10 closed out — a net gain of 3 holders — while 31 added to existing stakes and 19 trimmed.

The largest buyer was Samlyn Capital, opening a new position worth an estimated $16.5M. The largest seller was Deep Track Capital, exiting entirely with an estimated $9.16M sold.

  • 77 institutional investors held Inozyme Pharma (INZY) as of Q3 2023, up from 74 in Q2 2023.
  • Funds reported $205M of Inozyme Pharma stock for Q3 2023, up 7.6% quarter-over-quarter.
  • 13 funds opened new Inozyme Pharma positions in Q3 2023 and 10 closed out, a net change of +3 holders.
  • The largest Inozyme Pharma buyer in Q3 2023 was Samlyn Capital, an estimated $16.5M added.
  • The largest Inozyme Pharma seller in Q3 2023 was Deep Track Capital, an estimated $9.16M sold.

Based on aggregated 13F filings for Q3 2023.